Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ: AMLX · USD

$28.1

-0.19 (-0.7%)· Recorded snapshot

Market cap	3.5B
Net income (ttm)	-152.1M
EPS (ttm)	-$1.43
Shares out	125.5M
Volume	898,489
Beta	-0.09

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -152.1M
EPS (ttm): -$1.43
Market cap: 3.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ホールド

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-74.7

P25 n/aP50 n/aP75 n/a

ROIC-48.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AMLX indicators

Market & fundamental data

Available fields

181

Groups with data

Currency

USD

Showing 181 of 181 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001658551
Company name	Amylyx Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	03237H101
Earnings date	2026-11-09
Earnings time	bmo
Employees	136
Employees change	13
Employees growth	10.57%
Enterprise value	$3.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2022-01-07
Is primary listing	Yes
Is SPAC	No
ISIN number	US03237H1014
Last 10-K release date	2026-03-03
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.5B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$28.11
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	AMLX
U.S. state	Massachusetts
Website	https://amylyx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-5.09%
FCF / EV yield	-3.89%
FCF yield	-3.62%
Industry forward P/E	13.86x
Industry P/E	173.47x
P/B ratio	13.18x
Price / tangible book value	14.64x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.1M
ROA	-44.13%
ROA (5Y)	-42.6%
ROCE	-66.6%
ROE	-74.73%
ROE (5Y)	-86.06%
ROIC	-48.45%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	6
EPS growth years	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-140,000
Depreciation and amortization	$369,000
EBIT	$-162.1M
EBITDA	$-161.7M
EPS	$-1.43
FCF per share	$-1.01
Financing cash flow	$196.1M
Free cash flow	$-126.7M
Free cash flow minus SBC	$-154.6M
Gross profit	$-92.4M
Income taxes	$46,000
Investing cash flow	$-78.8M
Net borrowing	$190.7M
Net cash flow	$-9.2M
Net income	$-152.1M
Operating cash flow minus SBC	$-154.5M
Operating income	$-162.1M
Stock-based compensation	$27.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$2.15
Debt / equity	0.02
Long-term assets	$8.2M
Long-term liabilities	$4.2M
Net cash (debt)	$245.5M
Net cash / market cap	7.01%
Net cash growth	40.4%
Net debt / equity	-1.03
Piotroski F-Score	2
Property, plant and equipment	$4.7M
Shareholders' equity	$239.2M
Tangible book value	$239.2M
Tangible book value per share	$2.15
Total assets	$264.6M
Total cash	$250.8M
Total debt	$5.3M
Total liabilities	$25.4M
WACC	3.74%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$256.3M
Current liabilities	$21.2M
Current ratio	12.12
Net working capital	$-14.6M
Quick ratio	11.88
Working capital	$235.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-36.47%
Dividend yield	0%
Shareholder yield	-36.47%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$21.75
1D price change	-0.67%
1M price change	-6.21%
1M total return	-6.21%
1W price change	-3.86%
1W total return	-3.86%
1Y price change	94.38%
1Y return CAGR	94.47%
1Y total return	94.38%
20-day SMA	$27.69
200-day SMA	$19.92
3M price change	41.92%
3M total return	41.92%
3Y price change	75.73%
3Y return CAGR	20.67%
3Y total return	75.73%
50-day SMA	$31.30
50-day SMA vs 200-day SMA	50over200
52-week high	$41.14
52-week high date	2026-08-21
52-week low	$10.83
52-week low date	2026-01-05
6M price change	63.86%
6M total return	63.86%
All-time high	$41.93
All-time high date	2023-01-30
All-time low	$1.58
All-time low date	2024-06-17
Average true range (ATR)	$1.42
Average volume	1.3M
Beta (1Y)	0.3
Beta (2Y)	1.2
Beta (5Y)	-0.09
Change from 52-week high	-31.67%
Change from 52-week low	159.56%
Change from all-time high	-34.03%
Change from all-time low	1,656.19%
Change from open	0.75%
Day's gap	-1.41%
Dollar volume	$25.3M
High price	$28.35
Low price	$27.66
Monthly RSI	65.22
Open price	$27.90
Position in 52-week range	65.22%
Premarket change	0.49%
Premarket close	$28.30
Premarket price	$28.44
Premarket volume	9.5K
Previous close	$28.30
Price vs 150-day SMA	27.16%
Price vs 20-day SMA	-0.1%
Price vs 200-day SMA	38.84%
Price vs 50-day SMA	-11.63%
Relative volume	0.68
Return from IPO open	32.81%
Return from IPO price	46.79%
RSI	45.86
Sharpe ratio	1.09
Sharpe ratio (3Y)	0.79
Sortino ratio	2.69
Sortino ratio (3Y)	1.2
Volume	898.5K
Weekly RSI	57.74
YTD price change	128.97%
YTD total return	128.97%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	109.6M
Float percentage	87.3%
Shares change (QoQ)	0.57%
Shares change (YoY)	36.47%
Shares held by insiders	6.05%
Shares held by institutions	85.4%
Shares outstanding	125.5M
Short % of float	11.56%
Short % of shares	10.09%
Short ratio	8.2 days

Deeper analysis on AMLX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AMLX report

Is a complete AMLX research report available?

No complete published report is available for Amylyx Pharmaceuticals, Inc. (AMLX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Amylyx Pharmaceuticals, Inc. (AMLX)

Price

Financial snapshot

Fair-value bridge

Latest news · AMLX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AMLX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AMLX

Frequently asked questions